220 related articles for article (PubMed ID: 21549228)
1. Protein signatures for survival and recurrence in metastatic melanoma.
Hardesty WM; Kelley MC; Mi D; Low RL; Caprioli RM
J Proteomics; 2011 Jun; 74(7):1002-14. PubMed ID: 21549228
[TBL] [Abstract][Full Text] [Related]
2. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
[TBL] [Abstract][Full Text] [Related]
3. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis.
Spanknebel K; Coit DG; Bieligk SC; Gonen M; Rosai J; Klimstra DS
Am J Surg Pathol; 2005 Mar; 29(3):305-17. PubMed ID: 15725798
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis.
White RR; Stanley WE; Johnson JL; Tyler DS; Seigler HF
Ann Surg; 2002 Jun; 235(6):879-87. PubMed ID: 12035046
[TBL] [Abstract][Full Text] [Related]
5. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma.
Badgwell B; Xing Y; Gershenwald JE; Lee JE; Mansfield PF; Ross MI; Cormier JN
Ann Surg Oncol; 2007 Oct; 14(10):2867-75. PubMed ID: 17671814
[TBL] [Abstract][Full Text] [Related]
6. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
[TBL] [Abstract][Full Text] [Related]
7. Correlation of histopathologic characteristics to protein expression and function in malignant melanoma.
Welinder C; Pawłowski K; Szasz AM; Yakovleva M; Sugihara Y; Malm J; Jönsson G; Ingvar C; Lundgren L; Baldetorp B; Olsson H; Rezeli M; Laurell T; Wieslander E; Marko-Varga G
PLoS One; 2017; 12(4):e0176167. PubMed ID: 28445515
[TBL] [Abstract][Full Text] [Related]
8. Molecular oncogene markers and their significance in cutaneous malignant melanoma.
Konstadoulakis MM; Vezeridis M; Hatziyianni E; Karakousis CP; Cole B; Bland KI; Wanebo HJ
Ann Surg Oncol; 1998; 5(3):253-60. PubMed ID: 9607628
[TBL] [Abstract][Full Text] [Related]
9. Number of Excised Lymph Nodes Has No Impact on Relapse and Survival in Patients With Stage III Melanoma.
Tas F; Erturk K
Ann Plast Surg; 2019 Oct; 83(4):455-458. PubMed ID: 31524742
[TBL] [Abstract][Full Text] [Related]
10. Lymph node ratio has impact on relapse and outcome in patients with stage III melanoma.
Tas F; Erturk K
Int J Clin Oncol; 2019 Jun; 24(6):721-726. PubMed ID: 30788673
[TBL] [Abstract][Full Text] [Related]
11. Mitotic rate in node-positive stage III melanoma: it might be as important a prognostic factor as node number.
Tas F; Erturk K
Jpn J Clin Oncol; 2021 May; 51(6):873-878. PubMed ID: 33758939
[TBL] [Abstract][Full Text] [Related]
12. Wide local excision prior to sentinel lymph node biopsy for primary melanoma of the head and neck.
May MM; Lohse CM; Moore EJ; Price DL; Van Abel KM; Brewer JD; Janus JR
Int J Dermatol; 2019 Oct; 58(10):1184-1190. PubMed ID: 30968948
[TBL] [Abstract][Full Text] [Related]
13. Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.
Naffouje S; Naffouje R; Bhagwandin S; Salti GI
Melanoma Res; 2015 Dec; 25(6):496-502. PubMed ID: 26317170
[TBL] [Abstract][Full Text] [Related]
14. Outcome of patients with melanoma and histologically negative sentinel lymph nodes.
Gadd MA; Cosimi AB; Yu J; Duncan LM; Yu L; Flotte TJ; Souba WW; Ott MJ; Wong LS; Sober AJ; Mihm MC; Haluska FG; Tanabe KK
Arch Surg; 1999 Apr; 134(4):381-7. PubMed ID: 10199310
[TBL] [Abstract][Full Text] [Related]
15. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
16. Small and Isolated Immunohistochemistry-positive Cells in Melanoma Sentinel Lymph Nodes Are Associated With Disease-specific and Recurrence-free Survival Comparable to that of Sentinel Lymph Nodes Negative for Melanoma.
LeBlanc RE; Barton DT; Li Z; Angeles CV; Ernstoff MS; Bagley E; Wimmer D; Wong SL; Barth RJ; Shirai K; Yan S
Am J Surg Pathol; 2019 Jun; 43(6):755-765. PubMed ID: 31091203
[TBL] [Abstract][Full Text] [Related]
17. Judging the therapeutic value of lymph node dissections for melanoma.
Chan AD; Essner R; Wanek LA; Morton DL
J Am Coll Surg; 2000 Jul; 191(1):16-22; discussion 22-3. PubMed ID: 10898179
[TBL] [Abstract][Full Text] [Related]
18. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma.
Agrawal S; Kane JM; Guadagnolo BA; Kraybill WG; Ballo MT
Cancer; 2009 Dec; 115(24):5836-44. PubMed ID: 19701906
[TBL] [Abstract][Full Text] [Related]
19. [Prognosis after sentinel node biopsy in malignant melanoma].
Lock-Andersen J; Horn J; Sjøstrand H
Ugeskr Laeger; 2006 Jun; 168(25):2457-62. PubMed ID: 16824370
[TBL] [Abstract][Full Text] [Related]
20. Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma.
Strom T; Torres-Roca JF; Parekh A; Naghavi AO; Caudell JJ; Oliver DE; Messina JL; Khushalani NI; Zager JS; Sarnaik A; Mulé JJ; Trotti AM; Eschrich SA; Sondak VK; Harrison LB
J Natl Compr Canc Netw; 2017 Apr; 15(4):473-482. PubMed ID: 28404758
[No Abstract] [Full Text] [Related]
[Next] [New Search]
